Fluxion Biosciences Wins R&D 100 Award for the IonFlux HT System

R&D Magazine's Award for Technical Innovation Recognizes Fluxion’s IonFlux HT System as a Significant Advance for Life Science and Drug Discovery Research

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Fluxion Biosciences, a leading provider of functional cell analysis systems for drug discovery and diagnostics, today announced that it has won a 2010 R&D 100 Award for its IonFlux™ HT System. The R&D 100 Award places the state-of-the-art IonFlux System in the prestigious company of previous winners such as liquid crystal displays and the anticancer drug Taxol.

Known as "the Oscars of Invention", the R&D 100 Award showcases the most significant new technologies commercialized worldwide. This year, R&D Magazine recognized Fluxion for the superior performance and capabilities of the IonFlux HT System. The IonFlux HT, based on novel microfluidics and flow control technology, helps researchers identify and characterize drug candidates that modulate ion channels. Ion channels are membrane proteins which are key pharmaceutical targets in pain, CNS, and metabolic disorders.

Introduced in 2009, the IonFlux system is used globally by leading pharmaceutical companies including Novartis and Pfizer. IonFlux represents a dramatic departure from existing automated patch clamp systems for ion channel screening. It features a novel plate reader format that delivers exceptional performance and throughput in a convenient bench-top format. The system is available in a high throughput screening version, the IonFlux HT, which runs 384 well microfluidic plates and achieves throughput of 10,000 data points per day. The IonFlux 16 is also available for lower throughput applications and was designed with the individual lab budget in mind. The IonFlux 16 is priced similarly to a conventional patch clamp rig which brings the benefits of automated patch clamp systems within reach of all labs working with ion channels.

"We are honored to be recognized by R&D Magazine for our new microfluidic technology and to be ranked among the world's top technology innovators," said Cristian Ionescu-Zanetti, Ph.D., CTO and inventor of the IonFlux system’s core technology. "The IonFlux system is a significant step forward in ion channel screening performance, throughput, and cost. The platform enables researchers and pharmaceutical companies to target ion channels that are clinically important but historically have been difficult to screen. It's gratifying to see recognition of our commitment to providing enabling products and technologies that improve the discovery activities of our life science customers worldwide."

About Fluxion Biosciences

Fluxion Biosciences provides cellular analysis tools for use in critical life science research and drug discovery applications. Fluxion’s proprietary microfluidic platform enables precise functional analysis of individual cells in a multiplexed format. Products include the BioFlux™ system for studying cellular interactions, and the IonFlux™ system for high throughput ion channel screening. Fluxion’s systems meet the rigorous demands of life science and drug discovery scientists by providing an intuitive, easy-to-use operating system for single-cell biology. For more information about Fluxion Biosciences, visit www.fluxionbio.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6371473&lang=en



CONTACT:

Fluxion Biosciences
Mike Schwartz, 650-241-4737
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Pharmaceutical  Research  Other Science  Science

MEDIA:

Logo
 Logo
Photo
 Photo
IonFlux HT Automated Patch Clamp System for high throughput ion channel screening. (Photo: Business Wire)

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.